ESMO Congress 2024

September 13-17 | Booth #640 | Barcelona, Spain

September 13-17 | Booth #640 | Barcelona, Spain

Headed to the ESMO 2024?

Meet Our Experts at Booth #640

The oncology community will be at the ESMO Congress 2024, September 13-17, 2024 in Barcelona, Spain.

Stop by booth #640 to connect with our oncology clinical development experts. Our dedicated team will be there to discuss how to support your upcoming study from trial design and delivery to commercial optimization. Request a meeting to discuss your specific challenges or learn how we can help make intelligent connections to accelerate oncology clinical breakthroughs.

Attending Team:

Lyon Gleich, MD
Senior Vice President, Hematology & Oncology

Gaston Demonty, MD
Senior Medical Director, Hematology & Oncology

Cesar Casimiro, MD
Senior Medical Director, Hematology & Oncology

Beata Paluchowska, MD, PhD
Medical Director, Hematology & Oncology

Elliot Cohen, BS (Hons)
Senior Director, Clinical Trial Management

Sarah Jones, BSc (Hons)
Director, Clinical Trial Management

Stephanie Millin, PhD
Senior Clinical Trial Manager

Request a Meeting at ESMO

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.

An Integrated Approach to Global Clinical Research

Your oncology breakthrough starts here

Through our proven full-service outsourcing model, Medpace consistently delivers high-quality results, showcasing profound expertise in managing Phase I-IV trials. Operating in over 40 countries, we have earned a reputation for taking on some of the most complex and challenging cancer research studies.

  • Led by a team of medical, operational, and regulatory experts experienced in hematology and oncology
  • Integrated services and systems through out wholly-owned Central Laboratories, Bioanalytical Lab, Imaging Core Lab, ECG Core Lab, and Phase I Unit, in addition to our Clinical Trial Management System
  • Preferred provider relationships with key sites, expediting site start-up, enhancing recruitment, and maximizing trial efficacy
  • Experience in targeted, advanced, and radiation therapies